51³Ô¹ÏÍø

A new finger prick test to bring prenatal care to pregnant women wins second prize in 51³Ô¹ÏÍø's pioneering entrepreneurial programme for women.

Ana Luisa Neves (final year PhD student) has won the 2nd prize in 51³Ô¹ÏÍø College’s flagship women entrepreneurship programme Althea-51³Ô¹ÏÍø for her prototype finger prick test that brings prenatal care to pregnant women living in isolated areas. Ana’s team which included Andrea Rodriguez-Martinez (PhD student with CSM) pitched the idea for a single device to measure four health indicators for pregnant women, specifically designed to be used in remote and underdeveloped areas with minimal knowledge and training.

The Althea-51³Ô¹ÏÍø Programme is a unique collaboration between 51³Ô¹ÏÍø and the Althea Foundation, a social venture fund. Now in its third year, the initiative is designed to inspire a new generation of women in science, technology and business. Ana speaks below about how her team plans to develop their idea further and how the £6000 prize money will help. 

The idea

Our prototype is a revolutionary finger prick test that will finally bring prenatal care to pregnant women living in isolated areas, where they most lack it. Combining our mixed backgrounds (medicine, bioengineering and prototype engineering development), we created a device that performs the multiple tests recommended in pregnancy (i.e. glycaemia, HIV, Syphilis and Hepatitis B) – in a single drop of blood. This all-in-one device is an economic and effective option for the early identification of diseases with known impact on pregnancy, thus allowing a timely treatment and better health outcomes for both mother and baby. 

How did the idea come about?

Four years ago, I was working as a volunteer doctor in a small village in Mozambique, in a project to empower pregnant women by providing them relevant medical information on their health, and their babies' health. According to the World Organisation of Health, every single woman should be tested at least for four medical conditions (glycemia, hepatitis B, syphylis and HIV). This screening improves health outcomes for mothers and babies - but also reduces healthcare system costs. 

Back there, I realised that pregnant women did not have access to prenatal testing: they would either not get tested at all, or get their blood collected, transported for long distances and finally tested in suboptimal conditions. So my question was, what if we could find an efficient and affordable way to bring prenatal care to these women?

What happens next? 

Althea-51³Ô¹ÏÍø funding will be critical to secure intellectual property and to strengthen relationships with industry experts to develop our prototype.

Watch the interview with Ana and the other prize winners at the .